Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial.
BACKGROUND: Patients with atrial fibrillation (AF) are at significantly increased risk of stroke. Oral anticoagulants (OACs) substantially reduce this risk, with gains seen across the spectrum of baseline risk. Despite the benefit to patients, OAC prescribing remains suboptimal in the United Kingdom...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797056149289172992 |
|---|---|
| author | Holt, T Fitzmaurice, D Marshall, T Fay, M Qureshi, N Dalton, A Hobbs, F Lasserson, D Kearley, K Hislop, J Jin, J |
| author_facet | Holt, T Fitzmaurice, D Marshall, T Fay, M Qureshi, N Dalton, A Hobbs, F Lasserson, D Kearley, K Hislop, J Jin, J |
| author_sort | Holt, T |
| collection | OXFORD |
| description | BACKGROUND: Patients with atrial fibrillation (AF) are at significantly increased risk of stroke. Oral anticoagulants (OACs) substantially reduce this risk, with gains seen across the spectrum of baseline risk. Despite the benefit to patients, OAC prescribing remains suboptimal in the United Kingdom (UK). We will investigate whether an automated software system, operating within primary care electronic medical records, can improve the management of AF by identifying patients eligible for OAC therapy and increasing uptake of this treatment. METHODS/DESIGN: We will conduct a cluster randomised controlled trial, involving general practices using the Egton Medical Information Systems (EMIS) Web clinical system. We will randomise practices to use an electronic software tool or to continue with usual care. The tool will a) produce (and continually refresh) a list of patients with AF who are eligible for OAC therapy--practices will invite these patients to discuss therapy at the start of the trial--and b) generate electronic screen reminders in the medical records of those eligible, appearing throughout the trial. The software will run for 6 months in 23 intervention practices. A total of 23 control practices will manage their AF register in line with the usual care offered. The primary outcome is change in proportion of eligible patients with AF who have been prescribed OAC therapy after six months. Secondary outcomes are incidence of stroke, transient ischaemic attack, other major thromboembolism, major haemorrhage and reports of inappropriate OAC prescribing in the data collection sample--those deemed eligible for OACs. We will conduct a process evaluation in parallel with the randomised trial. We will use qualitative methods to examine patient and practitioner views of the intervention and its impact on primary care practice, including its time implications. DISCUSSION: AURAS-AF will investigate whether a simple intervention, using electronic primary care records, can improve OAC uptake in a high risk group for stroke. Given previous concerns about safety, especially surrounding inappropriate prescribing, we will also examine whether electronic reminders safely impact care in this clinical area. TRIAL REGISTRATION: http://ISRCTN 55722437. |
| first_indexed | 2024-03-06T19:19:18Z |
| format | Journal article |
| id | oxford-uuid:19835948-c2ca-4212-9b26-b31776d7aee6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:19:18Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:19835948-c2ca-4212-9b26-b31776d7aee62022-03-26T10:49:24ZAutomated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:19835948-c2ca-4212-9b26-b31776d7aee6EnglishSymplectic Elements at Oxford2013Holt, TFitzmaurice, DMarshall, TFay, MQureshi, NDalton, AHobbs, FLasserson, DKearley, KHislop, JJin, JBACKGROUND: Patients with atrial fibrillation (AF) are at significantly increased risk of stroke. Oral anticoagulants (OACs) substantially reduce this risk, with gains seen across the spectrum of baseline risk. Despite the benefit to patients, OAC prescribing remains suboptimal in the United Kingdom (UK). We will investigate whether an automated software system, operating within primary care electronic medical records, can improve the management of AF by identifying patients eligible for OAC therapy and increasing uptake of this treatment. METHODS/DESIGN: We will conduct a cluster randomised controlled trial, involving general practices using the Egton Medical Information Systems (EMIS) Web clinical system. We will randomise practices to use an electronic software tool or to continue with usual care. The tool will a) produce (and continually refresh) a list of patients with AF who are eligible for OAC therapy--practices will invite these patients to discuss therapy at the start of the trial--and b) generate electronic screen reminders in the medical records of those eligible, appearing throughout the trial. The software will run for 6 months in 23 intervention practices. A total of 23 control practices will manage their AF register in line with the usual care offered. The primary outcome is change in proportion of eligible patients with AF who have been prescribed OAC therapy after six months. Secondary outcomes are incidence of stroke, transient ischaemic attack, other major thromboembolism, major haemorrhage and reports of inappropriate OAC prescribing in the data collection sample--those deemed eligible for OACs. We will conduct a process evaluation in parallel with the randomised trial. We will use qualitative methods to examine patient and practitioner views of the intervention and its impact on primary care practice, including its time implications. DISCUSSION: AURAS-AF will investigate whether a simple intervention, using electronic primary care records, can improve OAC uptake in a high risk group for stroke. Given previous concerns about safety, especially surrounding inappropriate prescribing, we will also examine whether electronic reminders safely impact care in this clinical area. TRIAL REGISTRATION: http://ISRCTN 55722437. |
| spellingShingle | Holt, T Fitzmaurice, D Marshall, T Fay, M Qureshi, N Dalton, A Hobbs, F Lasserson, D Kearley, K Hislop, J Jin, J Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. |
| title | Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. |
| title_full | Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. |
| title_fullStr | Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. |
| title_full_unstemmed | Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. |
| title_short | Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. |
| title_sort | automated risk assessment for stroke in atrial fibrillation auras af an automated software system to promote anticoagulation and reduce stroke risk study protocol for a cluster randomised controlled trial |
| work_keys_str_mv | AT holtt automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT fitzmauriced automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT marshallt automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT faym automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT qureshin automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT daltona automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT hobbsf automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT lassersond automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT kearleyk automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT hislopj automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial AT jinj automatedriskassessmentforstrokeinatrialfibrillationaurasafanautomatedsoftwaresystemtopromoteanticoagulationandreducestrokeriskstudyprotocolforaclusterrandomisedcontrolledtrial |